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Summary.-An investigation was made into the effect of Corynebacterium parvum
therapy on cerebral tumours in mice. I.v. C. parvum caused a slight but significant
increase in the survival of BALB/c mice injected intracerebrally (i.c.) with not
more than 50 Meth A cells. C. parvum was most effective if given on the same
day or 5 days after tumour. If this interval was increased there was no effect.
Multiple i.v. injections were no more effective than a single dose. I.v. C. parvum
had no influence on the survival of C57BL mice injected i.c. with Lewis tumour
cells, and had little effect on the induction of i.c. or s.c. tumours by methylchol-
anthrene. It was concluded that C. parvum therapy was of little use in the treatment
of cerebral tumour in mice. The clinical implications of these findings are dis-
cussed.
THERE is extensive documentation of
the antitumour effect of Corynebacterium
parvum on a wide variety of solid and
ascitic murine tumours (Woodruff and
Boak, 1966; Halpern et al., 1966; Castro,
1974) and on its inhibitory effect on
naturally occurring metastases (Proctor,
Rudenstam and Alexander, 1973; Sadler
and Castro, 1975, 1976).
In a pilot study ofC. parvum treatment
for patients with malignant disease, 2 of
10 patients developed de novo cerebral
metastases, 5 and 9 months after starting
regular monthly infusions of C. parvum,
despite control of disease at other sites
(Castro and Osborn, in press). At present
there is no information on the effect
ofC. parvum on intracerebral (i.c.) tumour
growth. C. parvum is considered to act
by non-specific potentiation of the host's
immune response (Scott, 1974a) and it is
possible that i.c. tumours are protected
from destruction by immunological mech-
anisms by the blood-brain barrier (Hol-
man, 1972; Medawar, 1948).
The aim of this study in mice was
to determine the effect of parenteral C.
parvum on both the growth of i.c. inocu-




BALB/c and female C57BL/10 Sc Sn were
obtained from Olac (Southern) Ltd.
Corynebacterium parvum.-A formalin-
killed suspension of C. parvum (Wellcome,
strain CN 6134, batch PX 374, 7 mg dry
weight/ml) was injected i.v. as a dose of
0-466 mg diluted with normal saline to
0-2 ml, i.p. or s.c. as 0 7 mg in 0 1 ml of
undiluted solution. Control groups received
an equal volume of saline.
Tumours.-A methylcholanthrene-induc-
ed sarcoma (Meth A) first described by
Old et al. (1962) was used. It was maintained
in ascitic form by weekly passage of 0.1 ml
of malignant ascites into recipient BALB/c
mice. It is syngeneic for BALB/c, antigenic
and exhibits a good dose-response curve.
The Lewis lung carcinoma was grown
in C57BL mice. It originated as a spon-
taneous epidermoid lung carcinoma in a
female C57BL mouse in 1951 (Sugiura and
Stock, 1955) and has been maintained by
serial passage of s.c. tumour. When grown(. PARVUlAM AND INTRACEREBRAL MOUSE TUMOURS
s.c. it always metastasizes to the lungs
(Simpson-Herren, Sandford and Holmquist,
1974). Cell suspensions of the Lewis tumour
were prepared by incubation of tumour
fragments in 0.25% trypsin (Bactotrypsin,
Difco, diluted 1/20) in phosphate-buffered
saline (Courtenay, 1976). Cell viability was
determined with trypan blue.
The lungs of mice which had died after
i.c. injection of Lewis tumour cells were
inspected for macroscopic surface metastases,
after staining by infusing the trachea with
a dilute solution of Indian ink and fixing
in Fekete's solution (Wexler, 1966).
Intracerebral injection. Tumour cells
were suspended in 0 01-ml aliquots ofmedium
TC199. Injection was made by hand into
the right parietal region of ether-anaesthet-
ized mice. A 25-gauge sleeved needle was
employed to ensure uniform penetration to
3 mm (Albright et al., 1975). The technique
was rapid and easy, but there was an imme-
diate mortality of approximately 500. The
survival times of the mice were recorded.
Induction of tumour.-Cubes of methyl-
cholanthrene were made by placing crystal-
line 20-methylcholanthrene (Sigma) in a
test tube, and heating it over a Bunsen
until it had liquefied. The liquid was
poured into a Petri dish and allowed to
solidify. The methyleholanthrene was then
broken into small pieces. A 1-mm cube
of methyleholanthrene was implanted into
ether-anaesthetized BALB/c mice either s.c.
in the upper dorsum or i.c. through a burr
hole made with a dental drill in the right
parietal region. Mice with s.e. implants
were killed when the tumour was 1 cm in
diameter, and those with i.c. implants when
neurological signs of tumour were observed.
The brains of all mice which had died from
i.c. tumour were excised, fixed in formal
saline and examined histologically after
staining with haematoxylin and eosin.
Statistics-The median survival times
of the different groups of mice were cal-
culated by assuming normality of the
distribution of tolerances (measured in days)
and analysed using Student's t test.
RESULTS
Initial studies showed that i.c. injec-
tion of 50 or 100 Meth A cells produced
fatal tumours in all mice, and death
occurred within 2-3 weeks. However,
after s.c. injection of 100 cells, tumour
grew in only 50%/ of mice. C. parvum
was given i.v., i.p., or s.c. at the same
time as i.c. injection of 100 Meth A cells
to groups of 20 BALB/c mice. The
median survival time was determined
for each group ofmice (Table I). Control,
TABLE I.-Median Survival in Days,
+ s.d., after i.c. Injection of 100 Meth A
Cells. C. parvum was Given s.c., i.p.,
or i.v. at Time of Tumour Injection
C. parvum
Control s.c. i.p. iv.
14-543-11 15-3±106 15-7+1-6 16 0i 1-6
saline-treated mice lived for a median
of 14-5 days. Mice given i.v. C. parvum
lived the longest, with a median survival
of 16-0 days. However, there was no
significant difference in the survival of
mice given C. parvum when compared
with control mice.
The effect of i.v. C. parvumn was
then investigated in groups of 10 mice
inoculated i.c. with 50 Meth A cells
(Table II). When the vaccine was in-
jected at the same time as tumour
TABLE II. Median Survival in Days ± s.d., in 2 Experiments
after i.c. Injection of 50 Meth A Cells. C. parvum was Given i.v.
at Time of Tumour Injection, 5, 6 or 14 Days Later
Control
Exp.1 15 9 +0-8
Exp.II 18-2j1-8
* P < 0 05.
tP < 0 02.
C. parvum
Day 0 Day 5 Day 6 Day 14
18-3i1Ilt 178+1-2*
21-3±2.9* 17-8±2-4 19-6-m_2-1
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inoculation (Day 0) there was a slight
but statistically significant increase in
the lifetime (P = 005-0 02) of mice. If
the vaccine was given 5 days later, there
was some increase of survival (P 0.05)
but when the interval between C. parvum
and tumour was increased further it was
ineffective.
Survival of groups of 15 mice given
50 Meth A cells i.c. was determined after
multiple i.v. injections of C. parvunm
(Table III). When 2 doses of vaccine
TABLE III. Median Survival in Days
± 8.d. after i.c. Injection of 50 Meth A
Cells. C. parvum was Given i.v. on
Day 0, Days 0 and 1 or Days 0, 7 and 14
C. parvum
Control Day 0 Day 0, 1 Day 0, 7, 14
16-2±1-2 18-8±1-0* 18-7±1.4* 17-541-7
*P < 0-02.
were given, on the same day as tumour
and 24 h later, the slight increase of
lifespan of mice was similar to that after
one injection of C. parvum on Day 0.














Injections of 103, 102 or 50 dissociated
Lewis tumour cells were given i.c. into
groups of 11 and 14 C57BL mice. C.
parvum was given i.v. at the same time
as tumour inoculation. The median sur-
vival time of saline-treated mice injected
i.c. with 103 cells was 16-2 + 6-2 days
and that of C. parvum-treated animals
15*5 + 10 4. There was no significant
difference in the survival of these two
groups. Those mice given 102 or 50
Meth A cells had very varied survival
times, and a few animals in both the
control and experimental group survived.
In no mice were metastases observed in
the lungs.
Methylcholanthrene induction of tumour
A pellet of methylcholanthrene was
implanted either s.c. into 2 groups of 15
TABLE IV. Tumours Induced by i.c.
Implants cof Methylcholanthrene in
BALB/c Mice. C. parvum was Given








spindle Glial Squamous None
5 3 7 3
8 1 5 3
100
Days
FIG. 1.-Numbers of mice surviving after s.c. implantation of a methylcholanthrene pellet: saline-
treated mice, ; mice given C. parvum every 4 weeks,









FIG. 2. Number of mice surviving after i.c. implantation of a methylcholanthrene pellet: saline- treated mice, - ; mice given C. parvum every 4 weeks,
and 16 mice or i.c. into 2 of 22 and 23
mice. The animals in one group from
each experiment were given i.v. C. parvum
every 4 weeks. Mice were killed when
tumour was present. In those mice given
an s.c. implant, there was no difference
in the survival of mice injected with C.
parvum or saline (Fig. 1). In contrast,
those animals with an i.c. implant given
C. parvum had a greater lifespan than
control mice (Fig. 2). Fifty per cent
of the control group were dead after
160 days but 50% of the C. parvurn
group were still alive after 290 days.
However, although the survival of these
two groups was different, it was not
significant at the 500 level.
DISCUSSION
There are few clinical reports of
immunotherapeutic treatments for i.c.
neoplasms. Trouillas (1973) found a sig-
nificant increase in patient survival after
resection of cerebral glioma and immuno-
therapy with autologous tumour cells.
However, Bloom et al. (1973), in a pros-
pective trial, reported no benefit from
specific immunotherapy in patients with
glioblastoma multiforme.
Parenteral C. parvum is particularly
effective in the treatment of metastases
in rodents (Proctor et al., 1973; Sadler
and Castro, 1976). However, in a small
clinical study of C. parvum therapy,
2 of 10 patients developed brain meta-
stases, despite control ofperipheral disease
(Castro and Osborn (in prepn.)). There-
fore, an investigation was made into
the effects of C. parvum on i.c. tumour
in mice. In the absence of an available
tumour which metastasized to the brain,
2 non-brain tumours were chosen for
this study (Meth A, a methylcholanthrene-
induced sarcoma, and Lewis lung car-
cinoma) and low doses of these were
injected i.c. The action of C. parvum
on the induction of s.c. and i.c. tumour
by methylcholanthrene was also studied.
The responses of cerebral neoplasms
to C. parvum may differ from those
shown by systemic tumours because of
the blood-brain barrier (Holman, 1972).
The brain lacks a network of lymphatic
drainage (Humphrey and White, 1970)
and therefore antigen must reach the
lymphoid tissues primarily via the blood-
stream or must await wandering macro-
phages and lymphocytes to enter the
CNS. We found that the number of
cells required for i.c. tumour growth
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was much lower than that required for
successful s.c. growth, suggesting that
this site was indeed immunologically
privileged. However, there is evidence
to suggest that, in the brain, inefficient
antigen presentation to the immune
system mayresult in a poorimmunological
response, rather than a decreased ability
of antibody or sensitized lymphocytes
to enter the brain (Levy, Mahaley, and
Day, 1972; Hellstrom et al., 1968; Meda-
war, 1948; Denlinger et al., 1975).
J.v. C. parvum was able to cause a
slight but significant increase in the
survival of mice with i.c. Meth A cells,
but only if as few as 50 Meth A cells
had been injected. C. parvum was effec-
tive if administered at the same time
as tumour and there was some response
if it was given up to 5 days later, but
there was no effect once the tumour
was established. Multiple i.v. injections
were found to be no more effective than
a single one. A similar result has been
reported for s.c. tumour (Scott, 1974b).
However, there is no doubt that Meth A
tumour is sensitive to C. parvum when
grown at other sites (Castro, 1974). C.
parvum was found to have no influence
on the survival of mice given i.c. Lewis
tumour despite previous observations in
this laboratory that both the primary
s.c. tumour and its metastases are in-
hibited by C. parvum (Sadler and Castro,
1975, 1976). Neither was there any
significant effect on the induction of s.c.
or i.c. tumour by methylcholanthrene.
This last result is in contrast to the
studies of Baum and Baum (1974) who
reported an increased delay in the in-
duction of sarcomas by methylcholan-
threne after C. parvum treatment. Thus,
C. parvum therapy was found to be
of little use in the treatment of cerebral
tumour.
Non-specific immunostimulation by
FCA or BCG has also been reported to
have no effect on i.c. tumour growth
(Scheinberg et al.,: 1962; Albright et al.,
1975).- On the- other hand, specific im-
munotherapy given before i.c. injection
of tumour cells does inhibit their growth
(Medawar, 1948; Denlinger et al., 1975;
Scheinberg et al., 1962; Albright et al.,
1975), and the induction of tumours by
methylcholanthrene, as well as the in-
cidence of spontaneous tumours, is de-
decreased by pre-immunization with tu-
mour plus an adjuvant (Whitmire and
Huebner, 1972; Likhite, 1976).
We therefore conclude that C. parvum
therapy alone has little effect on i.c.
tumour growth in mice. A few patients
whoreceived C.parvumtherapydeveloped
brain metastases (Castro and Osborn,
(in prepn.)) and therefore, it is probable
that this vaccine has a similarly poor
effect in man.
The authors would like to thank Dr I.
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